Mosaic Holdings: "'Virus Patch' Proven 99.9% Effective in Eliminating Pneumonia Bacteria... Nationally Certified Test Approval"

[Asia Economy Reporter Yoo Hyun-seok] The ‘antiviral patch’ of Mosaic Holdings, the major shareholder of Gangwon, (BM JIKIMI-i VIRUS Patch, hereinafter referred to as Jikimi Patch) has officially been certified to have a 100% bacterial removal rate against pneumonia bacteria.

Mosaic Holdings announced on the 27th that the Jikimi Patch received a 99.9% efficacy recognition in a validity test against pneumonia bacteria conducted by a nationally accredited testing institution. Amid the global emergency caused by COVID-19, also known as Wuhan pneumonia, the Jikimi Patch has been verified to reduce pneumonia bacteria by nearly 100% within 24 hours, raising expectations for increased domestic and international sales.

At the end of February, Mosaic Holdings formally requested the Korea Conformity Laboratories (KCL), an affiliated organization of the National Institute of Technology and Standards under the Ministry of Trade, Industry and Energy, to conduct a pneumonia bacteria removal rate test and efficacy verification, and the test was conducted over about a month.

As a result of testing the Jikimi Patch’s liquid concentrate against Klebsiella pneumoniae ATCC 4352 at KCL, a 99.9% bacterial reduction rate was measured. The bacterial reduction reaction time was also recorded as 24 hours, verifying rapid efficacy. According to the KCL report, the pneumonia bacteria test results based on the domestic and international accredited test standard KCL-FIR-1002:2018 showed that the initial concentration of 9.3X10^4 (CFU/mL) decreased to less than 10 (CFU/mL) after 24 hours.

Mosaic Holdings is also promoting efficacy verification tests against the COVID-19 virus following the pneumonia bacteria removal rate test. Additionally, it is known to be developing various follow-up products using the Jikimi liquid in collaboration with Gangwon. Mosaic Holdings plans to create synergy in supplying the Jikimi Patch and product development by utilizing Gangwon’s overseas network, which has recently accelerated the overseas supply of COVID-19 diagnostic kits.

A company official stated, “The concentration appearing as less than 10 (CFU/mL) means the bacteria have been reduced to a level where they cannot be detected within 1 mL, which is the highest grade result achievable in the test,” adding, “More than one million units have already been sold within about 20 days of launch, and we have received sample quantities going to Australia, China, and Dubai, among others, showing a good response. We plan to expand domestic and international supply based on the verified data.”

He continued, “The Jikimi Patch has already been verified to have an antiviral effect of up to 87% against respiratory variant viruses such as SARS and MERS, but we wanted to prove its antibacterial and antiviral effects against pneumonia bacteria, so we conducted the test,” adding, “Since the results were more positive than expected, we hope it can contribute to consumer health and prevention amid the ongoing mask shortage caused by the prolonged COVID-19 situation.”

The Jikimi Patch, for which Mosaic Holdings has secured exclusive distribution rights and has begun full-scale domestic and international sales this month, is a product based on natural plant-derived ingredients such as eucalyptus oil, patchouli oil, and thyme oil. It has excellent functions in inhibiting the growth of viruses, bacteria, and fungi, making it effective for people with weak immunity or respiratory systems such as the bronchi and lungs.

This content was produced with the assistance of AI translation services.